Use: Labeled indications
- INDICATIONS AND USAGE Tazicef (ceftazidime for injection) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1.
Full indications and usage US FDA label
INDICATIONS AND USAGE Tazicef (ceftazidime for injection) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae, including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis; Escherichia coli; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae; and Staphylococcus aureus (methicillin-susceptible strains). 2.
Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa; Klebsiella spp.; Escherichia coli; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus; Klebsiella spp.; and Escherichia coli. 4.
Bacterial Septicemia caused by Pseudomonas aeruginosa, Klebsiella spp., Haemophilus influenzae, Escherichia coli, Serratia spp., Streptococcus pneumoniae, and S taphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6.
Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli. 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli, Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp.
(many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis. Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. Tazicef (ceftazidime for injection, USP) may be used alone in cases of confirmed or suspected sepsis.
Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. Tazicef may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient.
When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tazicef (ceftazidime) and other antibacterial drugs, Tazicef (ceftazidime) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.
When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
Contraindications
- Hypersensitivity to ceftazidime or other cephalosporins
Contraindications (US label) US FDA label
CONTRAINDICATIONS Tazicef is contraindicated in patients who have shown hypersensitivity to ceftazidime or the cephalosporin group of antibacterial drugs.
Dosing: Adult
- Usual adult dose: 1 g IV or IM every 8 to 12 hours
- Uncomplicated urinary tract infection: 250 mg every 12 hours
- Complicated urinary tract infection: 500 mg every 8 to 12 hours
- Bone and joint infections: 2 g IV every 12 hours
- Uncomplicated pneumonia; mild skin infections: 500 mg to 1 g every 8 hours
- Serious gynecologic or intra-abdominal infection; meningitis; life-threatening infection: 2 g IV every 8 hours
- CrCl 50 mL/min or less: 1 g load, then 31–50: 1 g q12h; 16–30: 1 g q24h; 6–15: 500 mg q24h; <5: 500 mg q48h
Dosage and administration (US label) US FDA label
DOSAGE AND ADMINISTRATION Dosage The usual adult dosage is 1 gram administered intravenously or intramuscularly every 8 to 12 hours. The dosage and route should be determined by the susceptibility of the causative organisms, the severity of infection, and the condition and renal function of the patient. The guidelines for dosage of Tazicef (ceftazidime for injection, USP) are listed in Table 3.
The following dosage schedule is recommended. Table 3. Recommended Dosage Schedule Dose Frequency Adult Usual recommended dosage 1 gram intravenous or intramuscular every 8 to 12 hours Uncomplicated urinary tract infection 250 mg intravenous or intramuscular every 12 hours Bone and joint infections 2 grams intravenous every 12 hours Complicated urinary tract infections 500 mg intravenous or intramuscular every 8 to 12 hours Uncomplicated pneumonia; mild skin and skin-structure infections 500 mg to 1 gram intravenous or intramuscular every 8 hours Serious gynecological and intra-abdominal infections 2 grams intravenous every 8 hours Meningitis 2 grams intravenous every 8 hours Very severe life-threatening infections, especially in immunocompromised patients 2 grams intravenous every 8 hours Lung infections caused by Pseudomonas spp. in patients with cystic fibrosis with normal renal function Although clinical improvement has been shown, bacteriologic cures cannot be expected in patients with chronic respiratory disease and cystic fibrosis. 30 to 50 mg/kg intravenous to a maximum of 6 grams per day every 8 hours Neonates (0 – 4 weeks) 30 mg/kg intravenous every 12 hours Infants and children (1 month – 12 years) 30 to 50 mg/kg intravenous to a maximum of 6 grams per day The higher dose should be reserved for immunocompromised pediatric patients or pediatric patients with cystic fibrosis or meningitis. every 8 hours Impaired Hepatic Function No adjustment in dosage is required for patients with hepatic dysfunction.
Impaired Renal Function Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate [GFR] <50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of 1 gram of ceftazidime may be given.
An estimate of GFR should be made to determine the appropriate maintenance dosage. The recommended dosage is presented in Table 4. Table 4. Recommended Maintenance Dosages of Tazicef (Ceftazidime for Injection, USP) in Renal Insufficiency NOTE: if the dose recommended in Table 3 above is lower than that recommended for patients with renal insufficiency as outlined in Table 4, the lower dose should be used.
Creatinine Clearance (mL/min) Recommended Unit Dose of Tazicef Frequency of Dosing 50 to 31 1 gram every 12 hours 30 to 16 1 gram every 24 hours 15 to 6 500 mg every 24 hours less than 5 500 mg every 48 hours When only serum creatinine is available, the following formula (Cockcroft's equation) 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function: Males: Creatinine clearance (mL/min) = Weight (kg) x (140 - age) 72 x serum creatinine (mg/dL) Females: 0.85 x male value In patients with severe infections who would normally receive 6 grams of Tazicef daily were it not for renal insufficiency, the unit dose given in the table above may be increased by 50% or the dosing frequency may be increased appropriately.
Further dosing should be determined by therapeutic monitoring, severity of the infection, and susceptibility of the causative organism. In pediatric patients as for adults, the creatinine clearance should be adjusted for body surface area or lean body mass, and the dosing frequency should be reduced in cases of renal insufficiency.
In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by 1 gram after each hemodialysis period. Tazicef (ceftazidime for injection, USP) can also be used in patients undergoing intraperitoneal dialysis and continuous ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of Tazicef may be given, followed by 500 mg every 24 hours.
In addition to IV use, Tazicef can be incorporated in the dialysis fluid at a concentration of 250 mg for 2 L of dialysis fluid. Note: Generally, Tazicef should be continued for 2 days after the signs and symptoms of infection have disappeared, but in complicated infections longer therapy may be required. Administration Tazicef may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh.
Intra-arterial administration should be avoided (see PRECAUTIONS). Intramuscular Administration For IM administration, Tazicef should be constituted with one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection. Refer to Table 5. Intravenous Administration The IV route is preferable for patients with bacterial septicemia, bacterial meningitis, peritonitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or pending.
For direct intermittent IV administration, constitute Tazicef as directed in Table 5 with Sterile Water for Injection. Slowly inject directly into the vein over a period of 3 to 5 minutes or give through the tubing of an administration set while the patient is also receiving one of the compatible IV fluids (see COMPATIBILITY AND STABILITY).
For IV infusion, constitute the 1-gram or 2-gram vial and add an appropriate quantity of the resulting solution to an IV container with one of the compatible IV fluids listed under the COMPATIBILITY AND STABILITY section. Intermittent IV infusion with a Y-type administration set can be accomplished with compatible solutions.
However, during infusion of a solution containing ceftazidime, it is desirable to discontinue the other solution. Freezing solutions of ceftazidime for injection is not recommended. Table 5. Preparation of Solutions of Tazicef Size Amount of Diluent to be Added (mL) Approximate Available Volume (mL) Approximate Ceftazidime Concentration (mg/mL) Intramuscular 1 gram vial 3 3.6 280 Intravenous 1 gram vial 10 10.6 95 2 gram vial 10 11.2 180 All vials of Tazicef as supplied are under reduced pressure.
When Tazicef is dissolved, carbon dioxide is released and a positive pressure develops. For ease of use please follow the recommended techniques of constitution described on the detachable Instructions for Constitution section of this insert. Solutions of Tazicef, like those of most beta-lactam antibacterial drugs, should not be added to solutions of aminoglycoside antibacterial drugs because of potential interaction.
However, if concurrent therapy with Tazicef and an aminoglycoside is indicated, each of these antibacterial drugs can be administered separately to the same patient.
Dosing: Altered kidney function
Ceftazidime is removed almost entirely by glomerular filtration (80% to 90% unchanged in urine). The US label gives a 1 g loading dose, then reduced maintenance doses when creatinine clearance (CrCl) is 50 mL/min or less, 1 g after each hemodialysis, and 500 mg daily on peritoneal dialysis. High levels in kidney impairment can cause seizures and encephalopathy.
Kidney function measure: Label uses CrCl (mL/min; Cockcroft–Gault); the text refers to GFR <50 mL/min.
Show full dosing details
- CrCl ≥60 mL/min
- CrCl >50: usual dose (label).
- CrCl 30–59 mL/min
- CrCl 51–59: usual dose. CrCl 31–50: 1 g every 12 hours (label Table 4). Loading dose 1 g; if the usual dose (label Table 3) is lower, use the lower dose; in severe infections the unit dose may be raised by 50% or the interval shortened (label).
- CrCl 15–29 mL/min
- CrCl 16–30: 1 g every 24 hours; CrCl 15: 500 mg every 24 hours (label Table 4). Loading dose 1 g; if the usual dose (label Table 3) is lower, use the lower dose; in severe infections the unit dose may be raised by 50% or the interval shortened (label).
- CrCl <15 mL/min (not on dialysis)
- CrCl 6–15: 500 mg every 24 hours; below 5: 500 mg every 48 hours (label Table 4; 5 itself not specified). Loading dose 1 g; if the usual dose (label Table 3) is lower, use the lower dose; in severe infections the unit dose may be raised by 50% or the interval shortened (label).
- Hemodialysis (intermittent)
- Loading dose 1 g, then 1 g after each hemodialysis period (label). Literature option (not label): thrice-weekly after each session, 1 g, 1 g and 2 g for organisms with MIC of 8 µg/mL or less, or 2 g, 2 g and 3 g for Pseudomonas aeruginosa (Tsai 2025). These regimens are not weight-adjusted and come mostly from small pharmacokinetic studies; confirm the actual last and next session before each dose. See the site guide Antibiotic Stewardship in Hemodialysis (/guides/antibiotic-stewardship-dialysis.html).
- Peritoneal dialysis
- Label: intraperitoneal dialysis or CAPD, loading dose 1 g, then 500 mg every 24 hours; ceftazidime can also be added to dialysis fluid at 250 mg per 2 L (label). For PD-associated peritonitis (ISPD 2022): intraperitoneal intermittent 1,000 to 1,500 mg daily (long dwell) or 20 mg/kg daily (short dwell); continuous loading dose 500 mg/L, then 125 mg/L in each exchange. Continuous cephalosporin doses may need about 25% more in patients with significant residual kidney function (ISPD 2022).
- CRRT
- Not in label; the cited CRRT review (Li 2020) lists only ceftazidime-avibactam, not ceftazidime alone. Specialist input.
- Dialyzable? Yes: hemodialysis or peritoneal dialysis may aid removal (label overdose section). Less than 10% protein bound.
- Monitoring CrCl for dose; seizures, nonconvulsive status epilepticus, encephalopathy, asterixis and myoclonia with high levels in kidney impairment (label); kidney function with aminoglycosides or loop diuretics.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual weight-based dose (label).
- eGFR 30–59
- Adjust CrCl for body surface area or lean body mass and reduce dosing frequency as in adults (label). No pediatric table.
- eGFR 15–29
- Adjust CrCl for body surface area or lean body mass and reduce dosing frequency as in adults (label). No pediatric table.
- eGFR <15 (not on dialysis)
- Adjust CrCl for body surface area or lean body mass and reduce dosing frequency as in adults (label). No pediatric table.
- Hemodialysis (intermittent)
- No pediatric dialysis dosing in label. Specialist input.
- Peritoneal dialysis
- No pediatric dialysis dosing in label. Specialist input.
- CRRT
- No pediatric CRRT data in the cited sources. Specialist input.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
Impaired Renal Function Ceftazidime is excreted by the kidneys, almost exclusively by glomerular filtration. Therefore, in patients with impaired renal function (glomerular filtration rate [GFR] <50 mL/min), it is recommended that the dosage of ceftazidime be reduced to compensate for its slower excretion. In patients with suspected renal insufficiency, an initial loading dose of 1 gram of ceftazidime may be given.
An estimate of GFR should be made to determine the appropriate maintenance dosage. The recommended dosage is presented in Table 4. Table 4. Recommended Maintenance Dosages of Tazicef (Ceftazidime for Injection, USP) in Renal Insufficiency NOTE: if the dose recommended in Table 3 above is lower than that recommended for patients with renal insufficiency as outlined in Table 4, the lower dose should be used.
Creatinine Clearance (mL/min) Recommended Unit Dose of Tazicef Frequency of Dosing 50 to 31 1 gram every 12 hours 30 to 16 1 gram every 24 hours 15 to 6 500 mg every 24 hours less than 5 500 mg every 48 hours When only serum creatinine is available, the following formula (Cockcroft's equation) 1 may be used to estimate creatinine clearance. The serum creatinine should represent a steady state of renal function: Males: Creatinine clearance (mL/min) = Weight (kg) x (140 - age) 72 x serum creatinine (mg/dL) Females: 0.85 x male value In patients with severe infections who would normally receive 6 grams of Tazicef daily were it not for renal insufficiency, the unit dose given in the table above may be increased by 50% or the dosing frequency may be increased appropriately.
Further dosing should be determined by therapeutic monitoring, severity of the infection, and susceptibility of the causative organism. In pediatric patients as for adults, the creatinine clearance should be adjusted for body surface area or lean body mass, and the dosing frequency should be reduced in cases of renal insufficiency.
In patients undergoing hemodialysis, a loading dose of 1 gram is recommended, followed by 1 gram after each hemodialysis period. Tazicef (ceftazidime for injection, USP) can also be used in patients undergoing intraperitoneal dialysis and continuous ambulatory peritoneal dialysis. In such patients, a loading dose of 1 gram of Tazicef may be given, followed by 500 mg every 24 hours.
In addition to IV use, Tazicef can be incorporated in the dialysis fluid at a concentration of 250 mg for 2 L of dialysis fluid. Note: Generally, Tazicef should be continued for 2 days after the signs and symptoms of infection have disappeared, but in complicated infections longer therapy may be required. Administration Tazicef may be given intravenously or by deep IM injection into a large muscle mass such as the upper outer quadrant of the gluteus maximus or lateral part of the thigh.
Intra-arterial administration should be avoided (see PRECAUTIONS). Intramuscular Administration For IM administration, Tazicef should be constituted with one of the following diluents: Sterile Water for Injection, Bacteriostatic Water for Injection, or 0.5% or 1% Lidocaine Hydrochloride Injection. Refer to Table 5. Intravenous Administration The IV route is preferable for patients with bacterial septicemia, bacterial meningitis, peritonitis, or other severe or life-threatening infections, or for patients who may be poor risks because of lowered resistance resulting from such debilitating conditions as malnutrition, trauma, surgery, diabetes, heart failure, or malignancy, particularly if shock is present or pending.
For direct intermittent IV administration, constitute Tazicef as directed in Table 5 with Sterile Water for Injection. Slowly inject directly into the vein over a period of 3 to 5 minutes or give through the tubing of an administration set while the patient is also receiving one of the compatible IV fluids (see COMPATIBILITY AND STABILITY).
For IV infusion, constitute the 1-gram or 2-gram vial and add an appropriate quantity of the resulting solution to an IV contain
Dosing: Pediatric
- Approved ages
- Neonates (0 to 4 weeks) and children (label dose table).
- Usual dose
- Neonates (0 to 4 weeks): 30 mg/kg IV every 12 hours (label). 1 month to 12 years: 30 to 50 mg/kg IV every 8 hours (higher dose for immunocompromised children, cystic fibrosis or meningitis) (label).
- Maximum dose
- 6 g/day (label).
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
Pediatric Use See DOSAGE AND ADMINISTRATION.
Dosing: Older adult
Geriatric use (US label) US FDA label
Geriatric Use Of the 2,221 subjects who received ceftazidime in 11 clinical studies, 824 (37%) were 65 and older while 391 (18%) were 75 and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater susceptibility of some older individuals to drug effects cannot be ruled out.
This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function (see DOSAGE AND ADMINISTRATION).
Dosage forms
Philippines
- Powder for injection: 1 g, 2 g, 500 mg
- Powder for solution for iv infusion: 1 g, 2 g
- Lyophilized powder for injection: 1 g
- Sterile powder for injection: 1 g
- Lyophilized powder for injection n: 1 g
- Powder for solution for injection: 1 g
Registered products in the Philippines
109 products registered with the Food and Drug Administration (FDA) Philippines list Ceftazidime as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Ceftazidime (as pentahydrate) with sodium carbonate (5 products) · Ceftazidime (as pentahydrate with sodium carbonate) with Sterile Water for Injection (1 product). Products registered under these spellings are included in the table and marked.
All registered products109
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AerumCeftazidime | 1 g Powder for Injection (IM/IV)Type I Clear Glass Vial with Gray Rubber Stopper and Aluminum Seal and Red Plastic Flip-Off Cap (Box of 10's) | Rx | Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DRP-8558 | Nov 10, 2029 | |
AetazCeftazidime (As Pentahydrate) | 1 g Powder for Injection (IM/IV)10 mL-capacity USP Type II Clear Glass Vial with Halogenated Butyl Rubber Stopper and Flip-off Seal [Box of 10's] | Rx | Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd.China | Dynasty Pharmaceuticals | DR-XY48643 | Mar 9, 2028 | |
AetazCeftazidime (as pentahydrate) | 1g Powder for Injection (IM/IV)10 mL- capacity USP Type II Clear Glass Vial with Halogenated Butyl Rubber Stopper and Flip-off Seal (Box of 10's) | Rx | Shenzhen China Resources Gosun Pharmaceuticals Co., Ltd.China | Dynasty Pharmaceuticals | DRP-13731 | Mar 9, 2028 | |
BizazolineCeftazidime | 1g Powder for injection (IV)Type II Transparent Glass Vial with bromobutyl stopper and gray aluminum flip-off seal (Box of 1's and 10's) | Rx | Laboratorio Reig Jofre S.A.España | Penta Labs Australia (Philippines) | DRP-7427 | Oct 25, 2027 | |
BizazolineCeftazidime | 2g Powder for Injection (IV)Type II Transparent Glass Vial with bromobutyl stopper and gray aluminum flip-off seal (Box of 1's and 10's) | Rx | LABORATORIO REIG JOFRE S.AEspaña | PENTA LABS AUSTRALIA (PHILIPPINES) | DRP-7428 | Oct 25, 2027 | |
1 g Powder for Injection (IM/IV)20 mL-capacity borosilicate glass vial with rubber stopper and alu-plastic caps (Box of 10's) | Rx | Chengdu Brilliant Pharmaceutical Co., Ltd.China | Aglobal Care, Inc. | DRP-15186 | May 22, 2029 | ||
CefbexaCeftazidime | 1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal (Box of 1's) | Rx | Vellinton HealthcareIndia | Pharmakon Biotec Inc.Importer: Pranish Inc. | DRP-14987-05 | Dec 20, 2028 | |
CefdimeCeftazidime (as Pentahydrate) | 1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | Southmed Pharma CorporationImporter: Aglobal Care, Inc. | DRP-6180-06 | Mar 13, 2029 | |
CefdimeCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)20 ml Capacity USP Type I Flint Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal in Monocarton (Box of 10’s) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Southmed Pharma CorporationImporter: AMB HK Enterprises Inc. | DRP-8473-03 | Jul 15, 2029 | |
CefedixCeftazidime (as pentahydrate) | 1g Powder for Injection (IM/IV)20 mL-capacity USP Type III Clear Glass Vial with grey butyl rubber stopper and blue coloured aluminum flip off seal (Box of 1's) | Rx | Scott-Edil Advance Research Laboratories & Education LimitedIndia | Teramedix Pharma Trading Inc. | DR-XY47818 | Mar 15, 2027 | |
CeftabrilCeftazidime (as pentahydrate) | 1 g Powder for Injection (I.M./I.V.)Clear colorless borosilicate glass vial with butyl rubber stopper and aluminum plastic cap (Box of 10's) | Rx | Chengdu Brilliant Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-18535 | Jul 28, 2031 | |
CeftacentCeftazidime (as pentahydrate) | 1 g Powder for Injection (I.M./I.V.)20 mL USP Type III clear glass vial sealed with grey butyl bromo stopper and pink colored flip-off + LDPE ampoule containing Sterile Water for Injection as diluent x 10 mL (Box of 1's) | Rx | Theon Pharmaceuticals LimitedIndia | Central West Medicale Inc.Importer: Greencore Pharma Inc. | DRP-11577-03 | Mar 31, 2027 | |
CeftadimeCeftazidime (As Pentahydrate) | 1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with gray butyl rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | Scott-Edil Advance Research Laboratories & Education LimitedIndia | Pharmakon Biotec Inc. | DR-XY48131 | Jul 1, 2027 | |
CeftadimeCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with gray butyl rubber stopper and aluminum flip-off seal (Box of 1 's) | Rx | Scott-Edil Advance Research Laboratories & Education LimitedIndia | Pharmakon Biotec Inc. | DRP-13426 | Jul 1, 2027 | |
CeftaflaxCeftazidime | 1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal (Box of 1's) | Rx | Vellinton HealthcareIndia | Teramedix Pharma Trading Inc.Importer: Pranish Inc. | DRP-14987-02 | Dec 20, 2028 | |
CeftakonCeftazidime (as pentahydrate) | 1 g Sterile Powder for Injection (I.M./I.V.)20 mL USP Type III clear glass vial sealed with 20 mm grey butyl rubber stopper and blue flip-off cap with aluminum seal (Box of 1's) | Rx | Sance Laboratories Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-9665 | Jul 15, 2031 | |
CEFTAMEDCEFTAZIDIME (AS PENTAHYDRATE) | 1 G POWDER FOR INJECTION (IV/IM)USP TYPE I CLEAR GLASS VIAL BOX OF 10'S | Rx | HANKOOK KORUS PHARM. CO., LTD.Republic of Korea | Importer: MG PRIME PHARMACEUTICAL, INC. | DR-XY43773 | Oct 2, 2029 | |
CeftamedzCeftazidime (as pentahydrate) | 1 g Sterile Powder for InjectionType I Transparent Glass vial with rubber stopper and red flip-off seal | Rx | Shandong Xier Kangtai Pharmaceuticals Co., Ltd.China | JF Draf Pharmaceuticals Corporation | DRP-3724 | Oct 8, 2028 | |
CeftanovaCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)10 mL-capacity USP type III clear glass vial with rubber stopper and aluminum orange flip-off seal (Box of 1's) | Rx | Finebiotics Pharma Ltd.India | Medinova Pharmaceutical Inc. | DRP-16459 | Mar 18, 2030 | |
CeftazicareCeftazidime | 1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal (Box of 1's) | Rx | Vellinton HealthcareIndia | Teramedix Pharma Trading Inc.Importer: Pranish Inc. | DRP-14987-01 | Dec 20, 2028 | |
CEFTAZIDENCeftazidime (as Pentahydrate) | 1 g Powder for Injection (IM/IV)20 ml Capacity USP Type I Flint Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal in Monocarton (Box of 10’s) Box of 10's | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., LtdChina | Cyden Medicale Trading Inc.Importer: AMB HK ENTERPRISES INC. | DRP-8473-02 | Jul 15, 2029 | |
CeftazigenCeftazidime | 1 g Powder For Injection (Im/Iv)1g USP Type I Colorless Glass Vial with butyl rubber stopper and violet flip-off cap (Box of 10's) | Rx | PHIL INTER PHARMA CO., LTD.Vietnam | Importer: LARGEN MED INC. | DRP-5391 | Dec 3, 2028 | |
1g Lyophilized Powder for Injection (IM/IV) n10 mL-capacity USP Type II Glass vial with rubber stopper and flip- off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Incorporated | DRP-14309 | Aug 16, 2028 | ||
Ceftazimed-1 PlusCeftazidime (as pentahydrate with sodium carbonate) with Sterile Water for InjectionVariant spelling | 1g Lyophilized Powder for Injection (IM/IV)In a box, 10 mL-capacity USP Type II Glass vial with rubber stopper and flip-off cap and Amber Glass Ampoule x 10 mL (diluent) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Dreamax Incorporated | DRP-14310 | Aug 16, 2028 | |
CeftazinCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)20 mL USP Type I Clear Glass Vial x with Burgundy Flip-off Seal (Box of 1's) | Rx | United Biotech Pvt. LimitedIndia | Delex Pharma International, Inc. | DRP-10468 | Mar 3, 2031 | |
CeftazisaphCeftazidime (as Pentahydrate) | 1 g Powder for Injection (IV/IM)Type I Flint Glass Vial with Grey Bromobutyl Rubber Stopper and Alu/PP Flip-Off Seal x 1's (Box of 1's and 10's) | Rx | Kilitch Drugs (India) Ltd.India | Nelpa Lifesciences, Inc.Trader: Sapphire Lifesciences Pvt. Ltd. | DRP-10684 | Nov 5, 2031 | |
CeftazivitCeftazidime (as pentahydrate) | 1g Powder for Injection (I.M. / I.V.)USP Type I Clear and Colorless Glass Vial with Rubber Stopper and Red Flip Off Seal Box of 1's and 10's | Rx | Vitalis S.A.C.I.Colombia | Pan-Ject Pharmaceuticals Corp.Trader: Vitalis S.A.C.I. | DRP-2395 | Mar 18, 2029 | |
CeftebasCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)USP type I Glass Vial with 5 mL Sterile Water for Injection (Box of 1's) | Rx | Neutro Pharma (Pvt.) Ltd.Pakistan | Raquel-Abbas Pharmaceuticals & General Merchandise | DR-XY38098 | Jun 22, 2030 | |
CeftibacCeftazidime (as Pentahydrate) | 1 g Powder for Injection (I.M./I.V.)USP Type I Vial with 10mL Diluent (Box of 1's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DR-XY37334 | Jan 12, 2030 | |
CeftibacCeftazidime (as Pentahydrate) | 1g Powder for Injection (I.M./I.V.)USP Type II vial Box of 10's | Rx | Singapore Pharmawealth Lifesciences, IncPhilippines | — | DR-XY37504 | Feb 17, 2030 | |
CeftibacCeftazidime (as Pentahydrate) | 1g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial (1g) + USP Type I Clear Glass Ampoule (5mL Sterile Water for Injection) (Box of 1's) | Rx | Harbin Pharmaceutical Group Co. Ltd. Gen. Pharm FactoryChina | Phil Pharmawealth, Inc.Importer: Endure Medical, Inc. | DRP-16748-01 | Jan 18, 2028 | |
CeftibacCeftazidime (as Pentahydrate) | 500 mg Powder for Injection (I.M/I.V.)USP Type I Clear Glass Vial (500 mg) + USP Type I Clear Glass Ampoule (5 mL Diluent) (Box of 1's) | Rx | Harbin Pharmaceutical Group Co. Ltd. Gen. Pharm FactoryChina | Phil Pharmawealth, Inc.Importer: Endure Medical, Inc. | DRP-16747-01 | Jan 7, 2028 | |
CeftibacCeftazidime (as Pentahydrate) | 500 mg Powder for Injection (IM/IV)USP Type I Clear Glass Vial + 5 mL LDPE Vial as Diluent (Box of 1's) | Rx | Singapore Pharmawealth Lifesciences, Inc.Philippines | — | DR-XY36467 | Aug 13, 2029 | |
CeftidinCeftazidime (as pentahydrate) | 2 g Powder for Injection (IM/IV)USP Type I Glass Vial x 20 mL (Box of 1's) | Rx | Lyka Labs LimitedIndia | Ambica International Corporation | DRP-6146 | May 8, 2030 | |
CefwideCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)20 mL USP Type I Flint Glass Vial with grey bromobutyl rubber stopper (Box of 1's) | Rx | Neon Laboratories Ltd.India | Ambica International Corporation | DRP-4916 | Nov 13, 2028 | |
Cestazid 1000Ceftazidime (as Pentahydrate) | 1 g Powder for Injection (I.M./I.V.)10 mL USP Type II Glass Vial + 10 mL LDPE Sterile Water for Injection (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-3389 | Nov 10, 2031 | |
DemicefCeftazidime (as pentahydrate) | 1 g Powder For Injection (IM/IV)20 mL clear colorless borosilicate glass vial with butyl rubber stopper and aluminium plastic cap (Box of 1's and 10's) | Rx | Chengdu Brilliant Pharmaceutical Co., Ltd.China | Philgen Pharmaceuticals Inc. | DRP-13427 | Feb 15, 2028 | |
DimzefCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)Clear colorless glass vial with rubber stopper and violet colored flip-off seal (Box of 10’s) | Rx | Chong Kun Dang Pharmaceutical Corp.Republic of Korea | Unimex, Inc. | DRP-2831 | Mar 19, 2028 | |
ElbazidCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)20 mL USP Type III clear glass vial sealed with grey butyl bromo stopper and pink colored flip-off + LDPE ampoule containing Sterile Water for Injection as diluent x 10 mL (Box of 1's) | Rx | Theon Pharmaceuticals LimitedIndia | Ellebasy Medicale Group Inc.Importer: Greencore Pharma Inc. | DRP-11577-02 | Mar 31, 2027 | |
Eozidime-1000Ceftazidime | 1 g Powder for Solution for Injection (I.M./I.V.)20 mL Clear Glass Vial (Box of 1's) | Rx | Zee Laboratories LimitedHimachal Pradesh India | Eon Pharmatek Inc. | DR-XY48221 | Jul 25, 2032 | |
ErazideCeftazidime | 1 g Powder for Injection (IM/IV)USP Type I clear and colorless glass vial x 10 mL Box of 1's | Rx | Brawn Laboratories Ltd.India | Pharmalife DistributionImporter: Ambica International Corporation | DRP-6053 | May 13, 2030 | |
FlazidemCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)Clear glass vial with rubber stopper and white flip-off seal (Box of 1’s) | Rx | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-950 | Oct 23, 2027 | |
FortumCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)Type III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | ACS Dobfar S.p.A.Italy | Sandoz Philippines Corporation | DR-XY16156 | Jun 4, 2029 | |
FortumCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)Type III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1’s) | Rx | ACS Dobfar S.p.A.Italy | Sandoz Philippines Corporation | DRP-11863 | Jun 4, 2029 | |
FortumCeftazidime (as pentahydrate) | 2 g Powder for Solution for IV InfusionType III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | ACS Dobfar S.P.A.Italy | Sandoz Philippines Corporation. | DR-XY3848 | Jun 4, 2029 | |
FortumCeftazidime (as pentahydrate) | 2 g Powder for Solution for IV InfusionType III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1’s) | Rx | ACS Dobfar S.P.A.Italy | Sandoz Philippines Corporation. | DRP-11853 | Jun 4, 2029 | |
FortumCeftazidime (as pentahydrate) | 500 mg Powder for Injection (IM/IV)Type III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1's) | Rx | ACS Dobfar S.p.A.Italy | Sandoz Philippines Corporation. | DR-XY16118 | Jun 4, 2029 | |
FortumCeftazidime (as pentahydrate) | 500 mg Powder for Injection (IM/IV)Type III clear glass vial with rubber stopper and aluminum flip-off seal (Box of 1’s) | Rx | ACS Dobfar S.p.A.Italy | Sandoz Philippines Corporation | DRP-11862 | Jun 4, 2029 | |
FortzidCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)20 mL Capacity USP Type I Flint Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal in Monocarton (Box of 10’S) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | AMB HK Enterprises Inc. | DRP-8473 | Jul 15, 2029 | |
ForzidCeftazidime (as pentahydrate) | 1 g Powder for Injection (I.M./I.V.)1 Vial (1 g) in a Box | Rx | PT. Dankos FarmaIndonesia | Lakeside Pharmaceuticals Phil., Inc. | DR-XY26592 | Sep 26, 2027 | |
FotaranCeftazidime (as pentahydrate) | 1 g Powder for Injection (IV/IM)20 mL USP Type III flint moulded vial with 20 mm grey bromobutyl rubber plug (Box of l's) | Rx | VHB Medi Sciences LimitedIndia | Brady Pharma Inc. | DR-XY47863 | Mar 31, 2027 | |
FROXETACeftazidime (as Pentahydrate) | 1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's) | Rx | NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China | LABMATE PHARMA INC.Importer: AGLOBAL CARE, INC. | DRP-6180-01 | Mar 13, 2029 | |
GozidimeCeftazidime | 1g Powder For Injection (IM/IV)15 mL USP Type III Flint Glass Vial (Box of 1's) | Rx | Yeluri Formulations Pvt. Ltd.India | Generic Option Pharma Corp. | DRP-12560 | Sep 2, 2027 | |
HacefCeftazidime (as pentahydrate) | 1 g Powder for Injection (I.M/I.V)USP Type I Vial x 1’s (Box of 10's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. Factory, EU Formulation WorkshopChina | Endure Medical, Inc. | DRP-16749 | Apr 18, 2031 | |
HacefCeftazidime (as Pentahydrate) | 1g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial (1g) + USP Type I Clear Glass Ampoule (5mL Sterile Water for Injection) (Box of 1's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DR-XY34160 | Jan 18, 2028 | |
HacefCeftazidime (as Pentahydrate) | 1g Powder for Injection (I.M./I.V.)USP Type I Clear Glass Vial (1g) + USP Type I Clear Glass Ampoule (5mL Sterile Water for Injection) (Box of 1's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DRP-16748 | Jan 18, 2028 | |
HacefCeftazidime (as Pentahydrate) | 2 g Powder for Injection (IM/IV)USP Type I Vial + 2 Ampoules x 5 mL Diluent | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm FactoryChina | Endure Medical, Inc. | DR-XY34508 | Apr 21, 2030 | |
HacefCeftazidime (as Pentahydrate) | 500 mg Powder for Injection (I.M/I.V.)USP Type I Clear Glass Vial (500 mg) + USP Type I Clear Glass Ampoule (5 mL Diluent) (Box of 1's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DR-XY34129 | Jan 7, 2028 | |
HacefCeftazidime (as Pentahydrate) | 500 mg Powder for Injection (I.M/I.V.)USP Type I Clear Glass Vial (500 mg) + USP Type I Clear Glass Ampoule (5 mL Diluent) (Box of 1's) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DRP-16747 | Jan 7, 2028 | |
HacefCeftazidime (as pentahydrate) | 500 mg Powder for Injection (IM/IV)USP Type I Vial x 1's (Box of 10’s) | Rx | Harbin Pharmaceutical Group Co., Ltd. General Pharm. FactoryChina | Endure Medical, Inc. | DRP-17405 | Apr 18, 2031 | |
HalcefCeftazidime (As Pentahydrate) | 1 g Powder For Injection (IM/IV)USP Type I transparent glass vial with 20 mm grey buty rubber stopper and aluminum flip off seal with coloured polypropylene plastic seal (Box of 1's) | Rx | Medisure Laboratories Pakistan Pvt LtdPakistan | Accesspoint International Trading Inc.Importer: Accesspoint International Trading, Inc. | DRP-11739 | Apr 22, 2027 | |
J-TazidimCeftazidime (as pentahydrate) | 1 g Powder for Injection (I.M / I.V)USP Type I Borosilicate Glass Vial (Box of 10's) | Rx | Dongkwang Pharm. Co., Ltd.Republic of Korea | Ellebasy Medicale TradingImporter: JLT PHARMA INC. | DRP-7950 | Jun 11, 2029 | |
KeftamCeftazidime (as Pentahydrate) | 1 g Powder for Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal / (Box of 1's) | Rx | NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China | THE CATHAY DRUG CO., INC.Importer: AGLOBAL CARE, INC | DRP-6180-03 | Mar 13, 2029 | |
KERAZINECeftazidime (as Pentahydrate) | 1 g Powder for Injection20 ml Capacity USP Type I Flint Vial with Grey Butyl Rubber Stopper and Aluminum Flip-off Seal in Monocarton (Box of 10’s) Box of 10's | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., LtdChina | PhilRx Pharma IncImporter: AMB HK ENTERPRISES INC. | DRP-8473-01 | Jul 16, 2029 | |
1 g Powder for Solution for IV Infusion10 mL-capacity soda-lime glass vial with rubber stopper and aluminum plastic caps (Box of 1's) | Rx | Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.China | Luoxin Pharmaceuticals (PH) Corp. | DRP-15159 | May 16, 2029 | ||
MedtazimeCeftazidime (As Sodium) | 1 g Powder For Injection (Im/Iv)20 mL Type I Glass Vial with Gray Bromobutyl Rubber Stopper and Sealed with Aluminum Plastic Flip-Off Seal Cap x 1's (Box of 1's) | Rx | Ananta Medicare LimitedIndia | Medinova Pharmaceutical, Inc. | DRP-14218 | Jul 28, 2028 | |
NoneCeftazidime (as Pentahydrate) | 1 g Powder for Injection (I.M./I.V.)10 mL USP Type II Glass Vial + 10 mL LDPE Sterile Water for Injection (Box of 1's) | Rx | Inject Care Parenterals Pvt. Ltd.India | RiteMED Phils., Inc.Importer: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-3389-02 | Sep 11, 2037 | |
NoneCeftazidime (as Pentahydrate) | 1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's and 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | Connectwell Pharma Inc.Importer: AGlobal Care, Inc. | DRP-6180-05 | Mar 13, 2029 | |
NoneCeftazidime (as Pentahydrate) | 1 g Powder for Injection (I.M/I.V)10mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's and 10's) | Rx | NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China | BELLUS LIFE SOLUTIONS, INC.Importer: AGLOBAL CARE, INC. | DRP-6180-02 | Mar 13, 2029 | |
NoneCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)USP Type I glass vial with aluminum red plastic flip-off cap (Box of 10's) | Rx | Sinopharm Zhijun (Shenzhen) Pharmaceutical Co., Ltd.China | Dynasty Pharmaceuticals | DR-XY40158 | Oct 11, 2030 | |
NoneCeftazidime | 1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-oof seal (Box of 1's) | Rx | Vellinton HealthcareIndia | Pranish Inc. | DRP-14987 | Dec 20, 2028 | |
NoneCeftazidime (as pentahydrate) | 1 g Powder for Injection (IV/IM)Clear Glass Vial with Red Flip-off Cap + 10 mL Clear Glass Ampoule Diluent (Water for Injection) in a Box (Box of 1's) | Rx | Bosch Pharmaceuticals (Pvt.) Ltd.Pakistan | Nueva Sunshine Phils., Inc.Importer: Sahar International Trading Inc. | DRP-13689-03 | Mar 5, 2029 | |
NovazidimeCeftazidime (as pentahydrate) | 1 g Powder for Injection (I.M./I.V.)USP Type III Flint Glass Vial with Grey Butyl Rubber Stopper and Yellow Flip-off seal (Box of l's) | Rx | Yeluri Formulations Pvt. Ltd.India | Medinova Pharmaceutical, Inc. | DRP-11601 | Mar 31, 2027 | |
OnetazidCeftazidime | 1 g Powder for Injection (IM/IV)USP Type I Clear and Colorless Vial x 10 mL (Box of 1's) | Rx | Brawn Laboratories LimitedIndia | One Pharma Marketing Inc.Importer: Ambica International Corporation | DRP-6053-02 | May 13, 2030 | |
QualicefCeftazidime (as pentahydarte) | 1 g Powder for Injection10 mL USP Type I clear and colorless glass vial (Box of 1's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Qualifirst Health Inc. | DR-XY41800 | Mar 13, 2028 | |
1 g Lyophilized Powder for Injection (IM/IV)10 mL-capacity USP Type II Glass vial with rubber stopper and flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Reta DrugImporter: Dreamax Incorporated | DRP-14309-01 | Aug 16, 2028 | ||
RobedimCeftazidime | 1 g Powder for Injection (IM/IV)USP Type I clear and colorless glass vial x 10 mL Box of 1's | Rx | Brawn Laboratories Ltd.India | RSG Pharma TradingImporter: Ambica International Corporation | DRP-6053-01 | May 13, 2030 | |
1 gram Powder for Injection (IM/IV)Glass vial with rubber stopper and alu-plastic caps (Box of 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Company LimitedChina | Golden Life Pharmaceutical Product DistributionTrader: Salubris Pharmaceuticals Limited | DRP-16515 | Apr 8, 2030 | ||
Sanzidime-1000Ceftazidime (as pentahydrate) | 1 g Powder for Injection (I.M./I.V.)Type I Glass Vial x 20 mL (Box of 1's) | Rx | Sance Laboratories Pvt. Ltd.India | AMB HK Enteprises Inc. | DRP-5571 | Nov 7, 2028 | |
SeftaCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)USP Type I Clear Glass Vial + 10 mL Ampoule Water for Injection (Box of 1's) | Rx | Geofman PharmaceuticalsPakistan | Sahar International Trading, Inc. | DR-XY38717 | Nov 3, 2030 | |
SherzidCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)Type III Clear and Colorless Glass Vial (Box of 1’s) | Rx | Yeluri Formulations Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Sherrington Pharmaceuticals Pvt. Ltd. | DRP-4783 | Oct 8, 2028 | |
SITI-ZIDECeftazidime (as pentahydrate) | 1 g Powder for Injection (IV/IM)Clear Glass Vial with Red Flip-off Cap + 10 mL Clear Glass Ampoule Diluent (Water for Injection) in a Box | Rx | Bosch Pharmaceuticals Pvt. Ltd.Pakistan | Sahar International Trading, Inc. | DRP-13689 | Mar 5, 2029 | |
SurtazidCeftazidime (as Pentahydrate) | 1g Powder for Injection (IV/IM)USP Type III Flint Glass Vial with Grey Butyl Rubber Stopper and Yellow Flip Off Seal (Box of 10's) | Rx | Yeluri Formulations Pvt. Ltd.India | Pharma-Surrey International, Inc. | DRP-10330 | Sep 10, 2031 | |
TarzidimeCeftazidime (as pentahydrate with sodium carbonate) | 1 g Powder for Injection (IM/IV)10 mL-capacity USP Type II clear glass vial enclosed with butyl rubber stopper and aluminum seal with blue flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., LtdChina | Philgen Pharmaceuticals Inc. | DRP-16422 | Mar 5, 2030 | |
TazicefCeftazidime(as pentahydrate) (with sodium carbonate) | 1g Powder for Injection(IM/IV)Clear Glass Vial with Rubber Stopper & Blue Flip-off Seal x 1 g (Box of 10’s) | Rx | Shin Poong Pharmaceutical Co., Ltd.Republic of Korea | Phil. Shinpoong Pharma, Inc. | DRP-289 | Jul 27, 2031 | |
TazidemCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)BP Type I Colorless Glass Vial x 1's Box of 1's | Rx | Samchundang Pharm. Co., Ltd.Republic of Korea | PharmAsia-Cuvest, Incorporated | DR-XY41116 | Aug 3, 2027 | |
TazidemCeftazidime | 1 g Powder for Injection (IM/IV)USP Type I clear and colorless glass vial x 10 mL (Box of 1’s) | Rx | Brawn Laboratories Ltd.India | Pharmasia-Cuvest IncorporatedImporter: Ambica International Corporation | DRP-6053-03 | May 13, 2030 | |
TazidexCeftazidime (as pentahydrate) | 1 g Powder For Injection (IM/IV)10 mL Capacity Type I Flint Vial Sealed With Grey Butyl Rubber Stopper And Aluminum Seal with Flip-off Plastic Cap x 1's (Box of 10's) | Rx | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.China | Philrx Pharma Inc. | DRP-18648 | Aug 12, 2031 | |
TazidimeCeftazidime (as pentahydrate) | 1 g Powder for Injection (I.V/I.M.)Clear glass vial with red Flip-off cap + 10 mL Clear glass ampoule Diluent (Water for Injection) in a box | Rx | Bosch Pharmaceuticals, Pvt. Ltd.Pakistan | Jalmedbase Pharma Corp.Importer: Sahar International Trading Inc. | DRP-13689-02 | Mar 5, 2029 | |
TazifCeftazidime | 1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal/ (Box of 1's) | Rx | Vellinton HealthcareIndia | Teramedix Pharma Trading Inc.Importer: Pranish Inc. | DRP-14987-03 | Dec 20, 2028 | |
TazilukeCeftazidime (as Pentahydrate) | 1 g Powder for Injection (I.M./I.V.)10 mL USP Type II Glass Vial + 10 mL LDPE Sterile Water for Injection Box of 1's | Rx | Inject Care Parenterals Pvt. Ltd.India | Alpace Pharmaceutical DistributorImporter: Ambica International CorporationTrader: Stallion Laboratories Pvt. Ltd. | DRP-3389-01 | Sep 22, 2037 | |
TazimCeftazidime (as Pentahydrate) | 1 g Powder for Injection (I.M./I.V.)USP Type III Clear Glass Vial (Box of 1's) | Rx | Sandoz GmbHAustria | Importer: Sandoz Philippines Corporation | DRP-4445 | Jul 26, 2027 | |
TaziseaCeftazidime (as pentahydrate) | 1g Powder For Injection (IV/IM)15 mL-capacity USP type III Clear Glass Vial with grey butyl rubber stopper and yellow color aluminum propylene flip-off seal (Box of l's) | Rx | Yeluri Formulations Pvt. Ltd.India | Seapharma International Inc. | DRP-11070 | Jan 21, 2027 | |
TazisheenCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)20 mL-capacity USP Type III clear glass vial with gray butyl rubber stopper and aluminum flip-off seal (Box of 1 's) | Rx | Scott-Edil Advance Research Laboratories & Education LimitedIndia | Farmacia SheenaImporter: Pharmakon Biotec, Inc. | DRP-13426-01 | Jul 1, 2027 | |
TazisheenCeftazidime | 1 g Powder for Injection (IM/IV)20- mL capacity clear glass vial with rubber stopper and magenta aluminum flip-off seal (Box of 1's) | Rx | Vellinton HealthcareIndia | Farmacia SheenaImporter: Pranish Inc. | DRP-14987-04 | Dec 20, 2028 | |
TazivexCeftazidime | 1 g Powder for Injection (IM/IV)Individually boxed Type II glass vial with brownish-yellow flip-off seal (Box of 10's) | Rx | Shandong Xier Kangtai Pharmaceutical Co., Ltd.China | Sannovex Pharmaceutical Distributor | DRP-2490 | Aug 3, 2028 | |
TriceftazCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)20 mL USP Type III clear glass vial sealed with grey butyl bromo stopper and pink colored flip-off + LDPE ampoule containing Sterile Water for Injection as diluent x 10 mL (Box of 1's) | Rx | Theon Pharmaceuticals LimitedIndia | Triple Tact Import & Export Corp.Importer: Greencore Pharma Inc. | DRP-11577-01 | Mar 31, 2027 | |
VidimeCeftazidime (as Pentahydrate) | 1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's and 10's) | Rx | NCPC Hebei Huamin Pharmaceutical Co., Ltd.China | Vintel Med EnterprisesImporter: Aglobal Care, Inc. | DRP-6180-04 | Mar 13, 2029 | |
ZatfecCeftazidime (as pentahydrate) | 500 mg Powder for Injection (IM/IV)USP Type II clear and colorless glass vial sealed with bromobutyl rubber stopper and blue flip-off seal + clear and colorless glass ampoule (Sterile Water for Injection as solvent) [Box of 1's] | Rx | Egyptian International Pharmaceutical Industries Co. (EIPICO)Egypt | Ambica International Corporation | DRP-7398 | Oct 9, 2027 | |
ZefadimeCeftazidime (as pentahydrate) | 1g Powder for Injection (I.M./I.V)USP Type III Flint Glass Vial with Grey Butyl Rubber Stopper and Yellow Flip-off seal (Box of 1's) | Rx | Yeluri Formulation Pvt. Ltd.India | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical, Inc. | DRP-11601-01 | Mar 31, 2027 | |
ZeftacareCeftazidime (as Pentahydrate) | 1 g Powder For Injection (I.M./I.V.)10 mL USP Type I borosilicate, clear transparent glass vial with gray butyl rubber stopper and aluminum cap with blue colored plastic flip-off seal (Box of 1's and 10's) | Rx | NCPC HEBEI HUAMIN PHARMACEUTICAL CO., LTD.China | AGLOBAL CARE, INC. | DRP-6180 | Mar 13, 2029 | |
ZeftasaveCeftazidime (as pentahydrate) | 1 g Powder for Injection (I.M./I.V.)USP Type I transparent glass vial with 20 mm grey butyl rubber stopper and aluminum flip off seal with coloured polypropylene plastic seal (Box of 10's) | Rx | Medisure Laboratories Pakistan (Pvt.) LimitedPakistan | Savelink Pharma And Trading CoImporter: Accesspoint International Trading Inc. | DRP-11739-01 | Apr 22, 2027 | |
ZeptrigenCeftazidime (as pentahydrate) | 1 g Powder for Injection (IM/IV)Type I Glass Vial Sealed with Grey Rubber Stopper and Green Aluminum Flip-Off Seal Box of 1's and Box of 10's (with plastic tray); Type I Glass Vial Sealed with Grey Rubber Stopper and Alucap Metallic Green Box of 1's and Box of 10's (with plastic tray) | Rx | PT Darya-Varia Laboratoria TbkIndonesia | UNILAB, INC. | DR-XY27651 | Oct 24, 2027 | |
ZeptrigenCeftazidime (as pentahydrate) | 500 mg Powder for Injection (IM/IV)Type I glass vial sealed with grey rubber stopper and green aluminum flip-off seal; grey rubber stopper and alucap metallic green seal (Box of 1's, Box of 10's (with plastic tray)) | Rx | PT Darya-Varia Laboratoria TbkIndonesia | UNILAB, Inc. | DR-XY27652 | Oct 24, 2027 | |
ZidicefCeftazidime (as Pentahydrate) | 1 g Powder for Injection (IM/IV)10 mL USP Type III Clear and Colorless Glass Vial Sealed with 20 mm Grey Bromobutyl Rubber Stopper and Pink Flip-off Seal (Box of 1's) | Rx | Zeiss Pharmaceuticals Pvt. Ltd.India | Sanimed Pharmaceuticals Inc. | DRP-6843 | Sep 23, 2031 | |
ZidimeCeftazidime (as pentahydrate) | 1 g Powder for Injection (I.M./I.V.)20 mL USP Type III Clear Glass Vial (Box of 1’s) | Rx | Makcur Laboratories LimitedIndia | Penta Labs Australia (Philippines)Trader: U Square Lifesciences Pvt. Ltd. | DRP-12364 | Jul 25, 2027 | |
ZidmaxCeftazidime (As Pentahydrate) | 1g Powder For Injection (I.M./I.V.)20 mL USP Type III clear glass vial sealed with grey butyl bromo stopper and pink colored flip-off + LDPE ampoule containing Sterile Water for Injection as diluent x 10 mL (Box of 1's) | Rx | Theon Pharmaceuticals LimitedIndia | Greencore Pharma Inc. | DRP-11577 | Mar 31, 2027 | |
(no brand name)Ceftazidime | 1 g Powder for Injection (IM/IV)20 mL-capacity clear glass vial with rubber stopper amd magenta aluminum flip-off seal (Box of 1's) | Rx | Vellinton HealthcareIndia | Pranish Inc. | DR-XY48948 | Dec 20, 2028 | |
(no brand name)Ceftazidime (as pentahydrate with sodium carbonate) | 1 g Powder for Injection (IM/IV)10 mL-capacity USP type II clear glass vial enclosed with butyl rubber stopper and aluminum seal with blue flip-off cap (Box of 10's) | Rx | Reyoung Pharmaceutical Co., Ltd.China | Khriz Pharma Trading Inc. | DR-XY49171 | Aug 15, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Warnings/Precautions
Warnings and precautions (US label) US FDA label
WARNINGS BEFORE THERAPY WITH TAZICEF IS INSTITUTED, CAREFUL INQUIRY SHOULD BE MADE TO DETERMINE WHETHER THE PATIENT HAS HAD PREVIOUS HYPERSENSITIVITY REACTIONS TO CEFTAZIDIME, CEPHALOSPORINS, PENICILLINS, OR OTHER DRUGS. IF THIS PRODUCT IS TO BE GIVEN TO PENICILLIN-SENSITIVE PATIENTS, CAUTION SHOULD BE EXERCISED BECAUSE CROSS- HYPERSENSITIVITY AMONG BETA-LACTAM ANTIBACTERIAL DRUGS HAS BEEN CLEARLY DOCUMENTED AND MAY OCCUR IN UP TO 10% OF PATIENTS WITH A HISTORY OF PENICILLIN ALLERGY.
IF AN ALLERGIC REACTION TO TAZICEF OCCURS, DISCONTINUE THE DRUG. SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including ceftazidime, and may range in severity from mild diarrhea to fatal colitis.
Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy.
CDAD must be considered in all patients who present with diarrhea following antibacterial drug use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibacterial drug use not directed against C. difficile may need to be discontinued.
Appropriate fluid and electrolyte management, protein supplementation, antibacterial drug treatment of C. difficile, and surgical evaluation should be instituted as clinically indicated. Elevated levels of ceftazidime in patients with renal insufficiency can lead to seizures, nonconvulsive status epilepticus (NCSE), encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia (see PRECAUTIONS).
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Aminoglycosides; potent loop diuretics (furosemide) | Adjust or monitor | Nephrotoxicity reported with cephalosporins given with these drugs (label). | Monitor kidney function. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedDrug interactions (US label) US FDA label
Drug Interactions Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibacterial drugs or potent diuretics such as furosemide. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibacterial drugs.
Nephrotoxicity and ototoxicity were not noted when ceftazidime was given alone in clinical trials. Chloramphenicol has been shown to be antagonistic to beta-lactam antibacterial drugs, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli. Due to the possibility of antagonism in vivo, particularly when bactericidal activity is desired, this drug combination should be avoided.
Adverse reactions
Common
- Local reactions after IV injection (phlebitis)
- Allergic reactions (rash, pruritus)
- Gastrointestinal effects (diarrhea, nausea)
Serious
- Anaphylaxis (cross-reactivity with penicillins up to 10%)
- Seizures, nonconvulsive status epilepticus, encephalopathy in kidney impairment
- Clostridioides difficile-associated diarrhea
Adverse reactions (US label) US FDA label
ADVERSE REACTIONS Ceftazidime is generally well tolerated. The incidence of adverse reactions associated with the administration of ceftazidime was low in clinical trials. The most common were local reactions following IV injection and allergic and gastrointestinal reactions. Other adverse reactions were encountered infrequently.
No disulfiram-like reactions were reported. The following adverse effects from clinical trials were considered to be either related to ceftazidime therapy or were of uncertain etiology: Local Effects, reported in fewer than 2% of patients, were phlebitis and inflammation at the site of injection (1 in 69 patients). Hypersensitivity Reactions, reported in 2% of patients, were pruritus, rash, and fever.
Immediate reactions, generally manifested by rash and/or pruritus, occurred in 1 in 285 patients. Toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme have also been reported with cephalosporin antibacterial drugs, including ceftazidime. Angioedema and anaphylaxis (bronchospasm and/or hypotension) have been reported very rarely.
Gastrointestinal Symptoms, reported in fewer than 2% of patients, were diarrhea (1 in 78), nausea (1 in 156), vomiting (1 in 500), and abdominal pain (1 in 416). The onset of pseudomembranous colitis symptoms may occur during or after treatment (see WARNINGS). Central Nervous System Reactions (fewer than 1%) included headache, dizziness, and paresthesia.
Seizures have been reported with several cephalosporins, including ceftazidime. In addition, encephalopathy, coma, asterixis, neuromuscular excitability, and myoclonia have been reported in renally impaired patients treated with unadjusted dosing regimens of ceftazidime (see PRECAUTIONS: General). Less Frequent Adverse Events (fewer than 1%) were candidiasis (including oral thrush) and vaginitis.
Hematologic Rare cases of hemolytic anemia have been reported. Laboratory Test Changes noted during clinical trials with Tazicef (ceftazidime for injection, USP) were transient and included: eosinophilia (1 in 13), positive Coombs test without hemolysis (1 in 23), thrombocytosis (1 in 45), and slight elevations in one or more of the hepatic enzymes, aspartate aminotransferase (AST, SGOT) (1 in 16), alanine aminotransferase (ALT, SGPT) (1 in 15), LDH (1 in 18), GGT (1 in 19), and alkaline phosphatase (1 in 23).
As with some other cephalosporins, transient elevations of blood urea, blood urea nitrogen, and/or serum creatinine were observed occasionally. Transient leukopenia, neutropenia, agranulocytosis, thrombocytopenia, and lymphocytosis were seen very rarely. Postmarketing Experience with Tazicef (ceftazidime for injection, USP) Products In addition to the adverse events reported during clinical trials, the following events have been observed during clinical practice in patients treated with Tazicef and were reported spontaneously.
For some of these events, data are insufficient to allow an estimate of incidence or to establish causation. General Anaphylaxis; allergic reactions, which, in rare instances, were severe (e.g., cardiopulmonary arrest); urticaria; pain at injection site. Hepatobiliary Tract Hyperbilirubinemia, jaundice. Renal and Genitourinary Renal impairment.
Cephalosporin-Class Adverse Reactions In addition to the adverse reactions listed above that have been observed in patients treated with ceftazidime, the following adverse reactions and altered laboratory tests have been reported for cephalosporin-class antibacterial drugs: Adverse Reactions Colitis, toxic nephropathy, hepatic dysfunction including cholestasis, aplastic anemia, hemorrhage. Altered Laboratory Tests Prolonged prothrombin time, false-positive test for urinary glucose, pancytopenia.
To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-438-1985, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Monitoring parameters
- CrCl for dose; seizures, nonconvulsive status epilepticus, encephalopathy, asterixis and myoclonia with high levels in kidney impairment (label); kidney function with aminoglycosides or loop diuretics. Kidney
- CrCl for dose
- Neurologic status in kidney impairment
- Kidney function with aminoglycosides or loop diuretics
Pregnancy considerations
Pregnancy (US label) US FDA label
Pregnancy Teratogenic Effects Pregnancy Category B. Reproduction studies have been performed in mice and rats at doses up to 40 times the human dose and have revealed no evidence of impaired fertility or harm to the fetus due to Tazicef. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Breastfeeding considerations
Lactation (US label) US FDA label
Nursing Mothers Ceftazidime is excreted in human milk in low concentrations. Caution should be exercised when Tazicef is administered to a nursing woman.
Pharmacokinetics
Key PK parameters
| Half-life | About 1.9 hours (IV) |
|---|---|
| Half-life in kidney failure (ESKD) kidney | Significantly prolonged in kidney impairment (label; no value given) |
| Protein binding | Less than 10% |
| Metabolism (CYP, transporters) | Not metabolized |
| Active metabolites | None |
| Renal excretion kidney | 80% to 90% unchanged in urine over 24 hours (glomerular filtration) |
| Dialyzability kidney | Yes (hemodialysis and peritoneal dialysis; label) |
The half-life following IV administration was approximately 1.9 hours.
The half-life of ceftazidime in these volunteers was approximately 2 hours.
Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period.
An additional 20% was excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose appeared in the urine between 4 and 8 hours later.
The mean renal clearance of ceftazidime was approximately 100 mL/min.
Pharmacokinetics (US label) US FDA label
CLINICAL PHARMACOLOGY After IV administration of 500-mg and 1-g doses of ceftazidime over 5 minutes to normal adult male volunteers, mean peak serum concentrations of 45 and 90 mcg/mL, respectively, were achieved. After IV infusion of 500-mg, 1-g, and 2-g doses of ceftazidime over 20 to 30 minutes to normal adult male volunteers, mean peak serum concentrations of 42, 69, and 170 mcg/mL, respectively, were achieved.
The average serum concentrations following IV infusion of 500-mg, 1-g, and 2-g doses to these volunteers over an 8-hour interval are given in Table 1 Table 1. Average Serum Concentrations of Ceftazidime Ceftazidime IV Dose Serum Concentrations (mcg/mL) 0.5 hr 1 hr 2 hr 4 hr 8 hr 500 mg 42 25 12 6 2 1 g 60 39 23 11 3 2 g 129 75 42 13 5 The absorption and elimination of ceftazidime were directly proportional to the size of the dose.
The half-life following IV administration was approximately 1.9 hours. Less than 10% of ceftazidime was protein bound. The degree of protein binding was independent of concentration. There was no evidence of accumulation of ceftazidime in the serum in individuals with normal renal function following multiple IV doses of 1 and 2 g every 8 hours for 10 days.
Following intramuscular (IM) administration of 500-mg and 1-g doses of ceftazidime to normal adult volunteers, the mean peak serum concentrations were 17 and 39 mcg/mL, respectively, at approximately 1 hour. Serum concentrations remained above 4 mcg/mL for 6 and 8 hours after the IM administration of 500-mg and 1-g doses, respectively.
The half-life of ceftazidime in these volunteers was approximately 2 hours. The presence of hepatic dysfunction had no effect on the pharmacokinetics of ceftazidime in individuals administered 2 g intravenously every 8 hours for 5 days. Therefore, a dosage adjustment from the normal recommended dosage is not required for patients with hepatic dysfunction, provided renal function is not impaired.
Approximately 80% to 90% of an IM or IV dose of ceftazidime is excreted unchanged by the kidneys over a 24-hour period. After the IV administration of single 500-mg or 1-g doses, approximately 50% of the dose appeared in the urine in the first 2 hours. An additional 20% was excreted between 2 and 4 hours after dosing, and approximately another 12% of the dose appeared in the urine between 4 and 8 hours later.
The elimination of ceftazidime by the kidneys resulted in high therapeutic concentrations in the urine. The mean renal clearance of ceftazidime was approximately 100 mL/min. The calculated plasma clearance of approximately 115 mL/min indicated nearly complete elimination of ceftazidime by the renal route. Administration of probenecid before dosing had no effect on the elimination kinetics of ceftazidime.
This suggested that ceftazidime is eliminated by glomerular filtration and is not actively secreted by renal tubular mechanisms. Since ceftazidime is eliminated almost solely by the kidneys, its serum half-life is significantly prolonged in patients with impaired renal function. Consequently, dosage adjustments in such patients as described in the DOSAGE AND ADMINISTRATION section are suggested.
Therapeutic concentrations of ceftazidime are achieved in the following body tissues and fluids. Table 2. Ceftazidime Concentrations in Body Tissues and Fluids Tissue or Fluid Dose/Route No. of Patients Time of Sample Post Dose Average Tissue or Fluid Level (mcg/mL or mcg/g) Urine 500 mg IM 6 0 to 2 hr 2,100 2 g IV 6 0 to 2 hr 12,000 Bile 2 g IV 3 90 min 36.4 Synovial fluid 2 g IV 13 2 hr 25.6 Peritoneal fluid 2 g IV 8 2 hr 48.6 Sputum 1 g IV 8 1 hr 9 Cerebrospinal fluid 2 g q8hr IV 5 120 min 9.8 (inflamed meninges) 2 g q8hr IV 6 180 min 9.4 Aqueous humor 2 g IV 13 1 to 3 hr 11 Blister fluid 1 g IV 7 2 to 3 hr 19.7 Lymphatic fluid 1 g IV 7 2 to 3 hr 23.4 Bone 2 g IV 8 0.67 hr 31.1 Heart muscle 2 g IV 35 30 to 280 min 12.7 Skin 2 g IV 22 30 to 180 min 6.6 Skeletal muscle 2 g IV 35 30 to 280 min 9.4 Myometrium 2 g IV 31 1 to 2 hr 18.7 Microbiology Mechanism of Action Ceftazidime is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis.
Ceftazidime has activity in the presence of some beta-lactamases, both penicillinases and cephalosporinases, of Gram-negative and Gram-positive bacteria. Mechanism of Resistance Resistance to ceftazidime is primarily through hydrolysis by beta-lactamase, alteration of penicillin-binding proteins (PBPs), and decreased permeability.
Interaction with Other Antimicrobials In an in vitro study, antagonistic effects have been observed with the combination of chloramphenicol and ceftazidime. Ceftazidime has been shown to be active against most isolates of the following bacteria, both in vitro and in clinical infections as described in the INDICATIONS AND USAGE section: Gram-negative bacteria
- Citrobacter species
- Enterobacter species
- Escherichia coli
- Klebsiella species
- Haemophilus influenzae
- Neisseria meningitidis
- Proteus mirabilis
- Proteus vulgaris
- Pseudomonas aeruginosa
- Serratia species Gram-positive bacteria
- Staphylococcus aureus
- Streptococcus pneumoniae
- Streptococcus pyogenes
- Streptococcus agalactiae Anaerobic bacteria
- Bacteroides species (Note: many isolates of Bacteroides species are resistant) The following in vitro data are available, but their clinical significance is unknown. At least 90 percent of the following microorganisms exhibit an in vitro minimum inhibitory concentration (MIC) less than or equal to the susceptible breakpoint for ceftazidime. However, the efficacy of ceftazidime in treating clinical infections due to these microorganisms has not been established in adequate and well-controlled clinical trials. Gram-negative bacteria
- Acinetobacter species
- Citrobacter diversus
- Citrobacter freundii
- Providencia species (including Providencia rettgeri)
- Salmonella species
- Shigella species
- Haemophilus parainfluenzae
- Morganella morganii
- Neisseria gonorrhoeae
- Yersinia enterocolitica Gram-positive bacteria
- Staphylococcus epidermidis Anaerobic bacteria
- Clostridium species (Not including Clostridium difficile)
- Peptostreptococcus species Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Ceftazidime 1 g Vial | ₱19.00–₱68.00Reference ₱34.00 | per vial | DPRI procurement range |
| Ceftazidime 500 mg Vial | ₱58.87–₱297.88Reference ₱288.44 | per vial | DPRI procurement range |
Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
Formulary and coverage
| Philippine National Formulary | Listed as Ceftaxidime (Ceftazidime) |
| PNF listing | Inj.: 250 mg, 500 mg and 1 g vial (IM, IV) (as pentahydrate) |
| PNF listing | Inj.: 2 g vial (IV infusion) (as pentahydrate) |
| PhilHealth GAMOT | No |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. TAZICEF · Hospira, Inc. [US FDA-approved label, version 16, May 4, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40d48c5d-650e-461b-a67b-7e65772d1b92
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Hospira, Inc. (2026). TAZICEF (ceftazidime for injection, USP) [Prescribing information; US FDA-approved label, ANDA062662, set ID 40d48c5d-650e-461b-a67b-7e65772d1b92, version effective May 4, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=40d48c5d-650e-461b-a67b-7e65772d1b92
- Tsai, Y. V., Soto, C., Crawford, G., & Dzintars, K. (2025). Important antimicrobial dosing considerations for transitions of care: Focus on thrice-weekly dosing in hemodialysis. American Journal of Health-System Pharmacy, 82(4), 203–210. https://doi.org/10.1093/ajhp/zxae259
- Li, P. K.-T., Chow, K. M., Cho, Y., Fan, S., Figueiredo, A. E., Harris, T., Kanjanabuch, T., Kim, Y.-L., Madero, M., Malyszko, J., Mehrotra, R., Okpechi, I. G., Perl, J., Piraino, B., Runnegar, N., Teitelbaum, I., Wong, J. K.-W., Yu, X., & Johnson, D. W. (2022). ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Peritoneal Dialysis International, 42(2), 110–153. https://doi.org/10.1177/08968608221080586
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .

